A Phase I/Ib Pilot Study of Combined Trabectedin and Venetoclax in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Resistant or Intolerant to a BTK Inhibitor
Latest Information Update: 03 Oct 2021
At a glance
- Drugs Trabectedin (Primary) ; Venetoclax (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions
Most Recent Events
- 11 Mar 2020 Planned End Date changed from 9 Apr 2020 to 4 Mar 2020.
- 11 Mar 2020 Planned primary completion date changed from 9 Apr 2020 to 4 Mar 2020.
- 11 Mar 2020 Planned initiation date changed from 1 Dec 2019 to 18 Jun 2019.